STOCK TITAN

BioForce Nanosciences HLD (BFNH) Financials

BFNH OTC
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income Not reported for the trailing 12 months
EPS (Diluted) $0.00 n/m YoY
Free Cash Flow Not reported for the trailing 12 months
Market Cap $248.2M as of Nov 16, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m no full year of net income reported yet
Price / Book 127x on $2.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BFNH SEC filings page.

This page shows BioForce Nanosciences HLD (BFNH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BFNH FY2025

Reported obligations dominate the balance sheet, while current assets and equity are deeply inadequate relative to liabilities.

From FY2024 to FY2025, total liabilities fell 73.1% while total assets fell only 8.8%, indicating a substantial liability reduction rather than broad asset growth. Yet current assets were only $786 against current liabilities of $619K; that imbalance is captured by a 0.0013x current ratio.

FY2025 reports negative equity of $619K and a retained-earnings deficit of $162.4M, so the liability reduction did not restore a positive capital base. The balance sheet remains financed by obligations exceeding recorded assets.

The filings provide no revenue, net income, or operating cash flow for FY2025, so they support a balance-sheet assessment rather than a conclusion about operating performance or cash conversion.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for BioForce Nanosciences HLD, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$342K
QoQ-243.2%

BioForce Nanosciences HLD reported a net loss of $342K in Q3 2026. Against the prior quarter it is down 243.2%.

EPS (Diluted)
-$0.01
YoYn/m
QoQ-200.0%

BioForce Nanosciences HLD earned -$0.01 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 200.0%.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$32K
YoY+3942.9%
QoQ+10224.4%
5Y CAGR+3.0%

BioForce Nanosciences HLD held $32K in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
38M
YoY+13.6%
QoQ+13.5%
5Y CAGR+5.4%

BioForce Nanosciences HLD had 38M shares outstanding in Q3 2026. This represents an increase of 13.6% from the same quarter a year earlier. Against the prior quarter it is up 13.5%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-17.4%
QoQ-27.8pp

BioForce Nanosciences HLD's quarterly ROE was -17.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 27.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

None of these metrics is reported for Q3 2026.

BFNH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFNH quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
SG&A Expenses$308K$119K$12K-56.8%N/AN/AN/A$28KN/A
Net Income-$342K$239KN/AN/AN/AN/AN/AN/A
EPS (Basic)-$0.01n/m$0.01n/m$0.00n/m$0.00n/m$0.00n/m$0.00n/m-$0.03n/m-$0.01n/m
EPS (Diluted)-$0.01n/m$0.01n/m$0.00n/m$0.00n/m$0.00n/m$0.00n/m-$0.03n/m-$0.01n/m
Diluted Shares (Avg)35M+4.5%34M+0.1%34M+4.0%N/A34M+14.5%34M+14.5%32M+10.2%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA, Interest Expense, Income Tax.

BFNH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFNH quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$2.2M+285443.5%$2.4M+263775.7%$6K-54.0%$786-8.8%$784-52.0%$905+35.7%$14K+2056.1%$862+35.1%
Current Assets$2.0M+255529.6%$2.2M+237861.3%$6K-54.0%$786-8.8%$784-52.0%$905+35.7%$14K+2056.1%$862+35.1%
Cash & Equivalents$32K+3942.9%$307-66.1%$6K-54.0%$786-8.8%$784-52.0%$905+35.7%$14K+2056.1%$862+35.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$277K-44.7%$85K-78.0%$727K+164.4%$619K-73.1%$501K-77.0%$385K-81.4%$275K-85.9%$2.3M+26.5%
Current Liabilities$277K-44.7%$85K-78.0%$727K+164.4%$619K-73.1%$501K-77.0%$385K-81.4%$275K-85.9%$2.3M+26.5%
Non-Current Liabilities$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Equity$2.0Mn/m$2.3Mn/m-$721Kn/m-$619Kn/m-$500Kn/m-$384Kn/m-$261Kn/m-$2.3Mn/m
Retained Earnings-$162.6Mn/m-$162.3Mn/m-$162.5Mn/m-$162.4Mn/m-$162.3Mn/m-$162.2Mn/m-$162.1Mn/m-$161.1Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BFNH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFNH quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$95K-$27K$7Kn/mN/AN/AN/A-$15KN/A
Financing Cash Flow$126K$21K-$2K-105.4%N/AN/AN/A$28KN/A

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BFNH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BFNH quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-17.4%10.4%N/AN/AN/AN/AN/AN/A
Return on Assets-15.3%10.0%N/AN/AN/AN/AN/AN/A
Current Ratio7.23+7.2x25.41+25.4x0.010.0x0.000.0x0.000.0x0.000.0x0.050.0x0.000.0x
Liabilities-to-Equity0.140.04N/AN/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$619K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

BioForce Nanosciences HLD (BFNH) reported diluted earnings per share of -$0.04 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioForce Nanosciences HLD (BFNH) had $786 in total assets as of fiscal year 2025, including both current and long-term assets.

BioForce Nanosciences HLD (BFNH) had 34M shares outstanding as of fiscal year 2025.

BioForce Nanosciences HLD (BFNH) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

BioForce Nanosciences HLD (BFNH) has no price-to-earnings ratio at the moment: no full year of net income reported yet. The market capitalization is $248.2M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

BioForce Nanosciences HLD (BFNH) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $248.2M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

BioForce Nanosciences HLD (BFNH) has negative shareholder equity of -$619K as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top